{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:54:17Z","timestamp":1795110857764,"version":"4.10.3"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.msard.2023.104718","type":"journal-article","created":{"date-parts":[[2023,4,16]],"date-time":"2023-04-16T09:25:36Z","timestamp":1681637136000},"page":"104718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study"],"prefix":"10.1016","volume":"74","author":[{"given":"Laura","family":"Dresser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Widad Abou","family":"Chaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Reder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Frisosky","family":"Abuaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica P.","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adil","family":"Javed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.104718_bib0033","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"JASN"},{"issue":"2","key":"10.1016\/j.msard.2023.104718_bib0041","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"22","key":"10.1016\/j.msard.2023.104718_bib0011","doi-asserted-by":"crossref","first-page":"e2504","DOI":"10.1212\/WNL.0000000000201260","article-title":"Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease","volume":"99","author":"Barreras","year":"2022","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2023.104718_bib0030","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2023.104718_bib0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00415-009-0009-0","article-title":"An epidemiological study of neuromyelitis optica in Cuba","volume":"256","author":"Cabrera-G\u00f3mez","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104718_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102428","article-title":"Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice","volume":"45","author":"Carnero Contentti","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2023.104718_bib0015","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104718_bib0018","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.msard.2023.104718_bib0043","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1212\/CON.0000000000000742","article-title":"Neuromyelitis optica spectrum disorder and other non-multiple sclerosis central nervous system inflammatory diseases","volume":"25","author":"Flanagan","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"issue":"5","key":"10.1016\/j.msard.2023.104718_bib0006","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2023.104718_bib0012","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","article-title":"Effectiveness of rituximab in neuromyelitis optica: a meta-analysis","volume":"19","author":"Gao","year":"2019","journal-title":"BMC Neurol."},{"issue":"4","key":"10.1016\/j.msard.2023.104718_bib0003","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/brain\/awab394","article-title":"Spectrum of sublytic astrocytopathy in neuromyelitis optica","volume":"145","author":"Guo","year":"2022","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.msard.2023.104718_bib0028","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s11064-013-1009-0","article-title":"Clinical relevance of serum aquaporin-4 antibody levels in neuromyelitis optica","volume":"38","author":"Isobe","year":"2013","journal-title":"Neurochem. Res."},{"issue":"9","key":"10.1016\/j.msard.2023.104718_bib0014","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2023.104718_bib0042","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V97.6.1817","article-title":"Interleukin-6 is a growth factor for nonmalignant human plasmablasts","volume":"97","author":"Jego","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.msard.2023.104718_bib0023","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints","volume":"22","author":"Jeong","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2023.104718_bib0031","first-page":"3603","article-title":"Mycophenolic acid differentially impacts b cell function depending on the stage of differentiation","volume":"187","author":"Karnell","year":"2011","journal-title":"J.I"},{"issue":"9","key":"10.1016\/j.msard.2023.104718_bib0013","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.msard.2023.104718_bib0009","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.msard.2023.104718_bib0002","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/WNR.0b013e32832776f4","article-title":"Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum","volume":"20","author":"Kinoshita","year":"2009","journal-title":"Neuroreport"},{"issue":"9451","key":"10.1016\/j.msard.2023.104718_bib0001","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.msard.2023.104718_bib0024","doi-asserted-by":"crossref","first-page":"e1316","DOI":"10.1002\/cti2.1316","article-title":"Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"10","author":"Lopez","year":"2021","journal-title":"Clin. Transl. Immunol."},{"issue":"Pt 7","key":"10.1016\/j.msard.2023.104718_bib0005","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"issue":"16","key":"10.1016\/j.msard.2023.104718_bib0025","doi-asserted-by":"crossref","first-page":"8946","DOI":"10.3390\/ijms22168946","article-title":"Th17-related cytokines as potential discriminatory markers between neuromyelitis optica (devic's disease) and multiple sclerosis-a review","volume":"22","author":"Maciak","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.msard.2023.104718_bib0032","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI200318384","article-title":"Azathioprine: old drug, new actions","volume":"111","author":"Maltzman","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.msard.2023.104718_bib0022","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2023.104718_bib0026","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jneuroim.2019.01.015","article-title":"The expansion of circulating IL-6 and IL-17-secreting follicular helper T cells is associated with neurological disabilities in neuromyelitis optica spectrum disorders","volume":"330","author":"Monteiro","year":"2019","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.msard.2023.104718_bib0007","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","article-title":"Worldwide incidence and prevalence of neuromyelitis optica: a systematic review","volume":"96","author":"Papp","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2023.104718_bib0040","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1212\/NXI.0000000000000061","article-title":"Disease exacerbation after rituximab induction in neuromyelitis optica","volume":"2","author":"Perumal","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5 Pt 1","key":"10.1016\/j.msard.2023.104718_bib0029","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am. J. Transplant."},{"issue":"7","key":"10.1016\/j.msard.2023.104718_bib0017","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2023.104718_bib0021","doi-asserted-by":"crossref","first-page":"e1645","DOI":"10.1212\/WNL.0000000000009245","article-title":"Evaluation of efficacy and tolerability of first-line therapies in NMOSD","volume":"94","author":"Poupart","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104718_bib0034","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0889-8553(21)00426-X","article-title":"6-mercaptopurine and other immunosuppressive agents in the treatment of crohn's disease and ulcerative colitis","volume":"18","author":"Present","year":"1989","journal-title":"Gastroenterol. Clin. North Am."},{"key":"10.1016\/j.msard.2023.104718_bib0038","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2023.104718_bib0035","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0016-5085(99)70445-2","article-title":"Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American azathioprine study group","volume":"117","author":"Sandborn","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.msard.2023.104718_bib0039","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0966-3274(03)00059-5","article-title":"Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys","volume":"12","author":"Schr\u00f6der","year":"2003","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.msard.2023.104718_bib0027","article-title":"Th17 cells and inflammation in neurological disorders: possible mechanisms of action","volume":"13","author":"Shi","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.msard.2023.104718_bib0010","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2023.104718_bib0037","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"Van der Kolk","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.msard.2023.104718_bib0004","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.4049\/jimmunol.181.8.5730","article-title":"Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment","volume":"181","author":"Vincent","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2023.104718_bib0036","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/S0140-6736(71)90268-6","article-title":"Controlled trial of azathioprine in Crohn's disease","volume":"2","author":"Willoughby","year":"1971","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.msard.2023.104718_bib0008","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2023.104718_bib0019","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823002225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:08:01Z","timestamp":1761901681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823002225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":43,"alternative-id":["S2211034823002225"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104718","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of rituximab versus oral immunosuppressive therapies in neuromyelitis optica spectrum disorder in a racially diverse cohort of subjects: A single-center retrospective study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104718","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104718"}}